COMMUNIQUÉS West-GlobeNewswire

Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
20/04/2026
SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products, [...]
Integra LifeSciences to Host First Quarter 2026 Financial Results Conference Call on May 5, 2026
20/04/2026
PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release first quarter 2026 financial results on Tuesday, [...]
Novo Nordisk A/S - share repurchase programme
20/04/2026
Bagsværd, Denmark, 20 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy
20/04/2026
Inside Information The ALLIANCE phase 2 trial demonstrated proof-of-concept after only 6 months of maintenance treatment in a broad patient population comprising both children and adults. Clear dose-dependent and [...]
Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing
20/04/2026
Superior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor models Novel RNA spliceosome-targeting payload PH1 shows potential to overcome Topoisomerase I inhibitor resistance [...]
Omega Laboratories to Host Educational Panels and Present Cannabix Marijuana Breath Test Solution at the 2026 NDASA Conference in California
20/04/2026
VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) a developer of marijuana and alcohol breath-testing [...]
Avicanna Announces Agenda for 6th Annual Clinical Symposium on Cannabinoid Therapeutics
20/04/2026
An established forum for evidence-based clinical discussion, interdisciplinary dialogue, and patient considerations Event is expanded to two days, live and virtual on June 11-12, 2026, at the MaRS Discovery District, [...]
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
20/04/2026
DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in [...]
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
20/04/2026
• Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final activation stages SARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical- [...]
First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases
20/04/2026
First Tracks Biotherapeutics launches with $180 million in cash and two-year cash-runway Trading of TRAX begins on Nasdaq today SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: [...]
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
20/04/2026
CAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]
Tilray Brands Marks 4/20, Reaffirming Its Leadership in Cannabis and Commitment to Advancing Medical Care
20/04/2026
NEW YORK and LEAMINGTON, Ontario, April 20, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of [...]
AVIS À IGNORER -- BVI Medical, Inc.
20/04/2026
WALTHAM, Mass., 20 avr. 2026 (GLOBE NEWSWIRE) -- BVI Medical, Inc. nous informe que les journalistes et autres lecteurs doivent ignorer le communiqué de presse publié le 20 avril 2026, « BVI annonce l’obtention du [...]
Baba Appoints Former Mount Sinai Executive Director to Lead Clinical Operations
20/04/2026
Platform taps decade+ of health system clinical leadership to scale virtual, longitudinal advocacy for Medicare, Medicare Advantage, and Medicaid populations NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Baba, an [...]
Vystar Enters into Binding Letter of Intent to Acquire 50% Interest in R3alm Inc.
20/04/2026
A Compliance-Focused AI and Web3 Financial Ecosystem Proposed Transaction Includes Joint Development Framework, Vystar Series B Consideration, and Strategic Alignment Around the R3EQ Ecosystem ■ ■ ■ Vystar to Receive [...]
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
20/04/2026
Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholders Launches with virtual model, including limited FTEs and minimal operating expenses, and approximately $140-$145 million in [...]
Scilex Holding Company Announces Its Board of Directors Approved a Dividend of Dream Bowl I Meme Coin Tokens to Holders of Common Stock and other Eligible Equity Securities with a Record Date of April 30, 2026
20/04/2026
PALO ALTO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non [...]
Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA
20/04/2026
ORION CORPORATION PRESS RELEASE 20 APRIL 2026 at 16.00 EEST Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA Orion Corporation (Orion Pharma) today announced that its investigational [...]
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
20/04/2026
Analysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alterations are rare, supporting observed durable first-line activity Atebimetinib-treated tumors rarely acquire the [...]

Pages